Idiopathic Pulmonary Fibrosis Market Size Report, Share, Industry Analysis, Growth, 2032

Idiopathic Pulmonary Fibrosis Industry Prospective:

The global idiopathic pulmonary fibrosis market size was worth around USD 3,763.90 million in 2023 and is predicted to grow to around USD 6,804.23 million by 2032 with a compound annual growth rate (CAGR) of roughly 6.80% between 2024 and 2032.

Request Free Sample

Idiopathic Pulmonary Fibrosis Market: Overview

Idiopathic pulmonary fibrosis (IPF) is a type of medical condition that leads to scarring of the lungs. IPF is the most common type of pulmonary fibrosis and the word ‘idiopathic’ denotes the absence of a valid cause. Scarring, also known as fibrosis, further leads to stiffness in the lungs which makes it difficult for the patient to breathe. Damage caused to the lungs due to IPF cannot be treated. It is a progressive condition thus the patient’s symptoms continue to worsen as time passes. Using certain medications, the progress of the condition can be slowed in certain cases. However, the most commonly recommended medical intervention for idiopathic pulmonary fibrosis is lung transplant. In addition to this, patients with IPF are recommended to maintain a healthy lifestyle by eating well and staying active along with seeking oxygen therapy. It is a rare medical condition and the symptoms include extreme tiredness, dry cough, shortness of breath, unintended weight loss, clubbing, and aches in joints or muscles. The average survival rate of a patient with IPF is between 3 to 5 years. IPF is known to affect around 20 out of every 100,000 people. The demand for IPF treatment is likely to witness steady growth during the forecast period.

Key Insights:

• As per the analysis shared by our research analyst, the global idiopathic pulmonary fibrosis market is estimated to grow annually at a CAGR of around 6.80% over the forecast period (2024-2032)
• In terms of revenue, the global idiopathic pulmonary fibrosis market size was valued at around USD 3,763.90 million in 2023 and is projected to reach USD 6,804.23 million, by 2032.
• The idiopathic pulmonary fibrosis market is projected to grow at a significant rate due to the growing awareness of IPF
• Based on the treatment centers, the hospital's segment is growing at a high rate and will continue to dominate the global market as per industry projection
• Based on the drug type, the pirfenidone segment is anticipated to command the largest market share
• Based on region, North America is projected to dominate the global market during the forecast period

Request Free Sample

Idiopathic Pulmonary Fibrosis Market: Growth Drivers

Growing awareness about IPF will drive the market demand rate

The global idiopathic pulmonary fibrosis market is projected to grow due to the increasing awareness about IPF across the globe. The condition typically occurs in middle-aged and older adults as per market research. However, it has also been diagnosed in children in certain cases. Since the condition cannot be cured more healthcare institutes and agencies are focusing on generating awareness about IPF and its management. For instance, the Pulmonary Fibrosis Foundation initiated the ‘Embrace Your Breath’ project in September 2024. The agency aims to raise understanding and knowledge about the condition and the measures that can help patients navigate through IPF. In November 2020, the Pulmonary Fibrosis Foundation also announced the commencement of Pinpoint PF. It is an education and awareness campaign aimed at people with higher risk and symptoms of pulmonary fibrosis (PF).

Growing access to healthcare worldwide will generate higher revenue during the projection period

Access to quality healthcare is a key requirement and necessity for the global population. In recent times, there has been significant growth in the number of initiatives and projects to promote healthcare accessibility among all segments of the population group including patients from low and mid-income backgrounds. For instance, in April 2024, the US Food & Drugs Administration announced the launch of Home as a Health Care Hub. The initiative is expected to incorporate home settings or the environment as a crucial part of the overall health system. The end goal is to achieve improved health equity among the US citizens. In April 2024, the World Bank Group announced a highly ambitious initiative. The agency expects to support countries in delivering affordable and quality health services to more than 1.5 billion people by the end of the decade. The initiative is a part of the global effort to provide basic necessities across several stages of a person’s life thus also contributing to the global idiopathic pulmonary fibrosis market.

Idiopathic Pulmonary Fibrosis Market: Restraints

Lack of IPF cure to act as a major growth restraining factor

The global industry for idiopathic pulmonary fibrosis is projected to be restricted due to the lack of 100% effective treatment for the condition. IPF is a progressive and chronic medical disease that cannot be cured. In the UK, more than 4500 deaths due to IPF were reported in 2024 as per the Office of National Statistics. Moreover, diagnosing the condition at early stages can be difficult since the disease does not have any underlying causes. The lack of suitable diagnostic infrastructure in certain parts of the world further limits the market expansion rate.

Idiopathic Pulmonary Fibrosis Market: Opportunities

Ongoing research for advancements in disease diagnosis and treatment will generate massive growth opportunities

The global idiopathic pulmonary fibrosis market is projected to generate excellent growth opportunities during the projection period. The ongoing extensive research in upgrading the diagnostic and treatment technologies will help the market players thrive in the future. For instance, in June 2024, the UK-based National Health Service (NHS) published information about a new study that is underway and funded by Asthma and Lung UK. The research aims to develop and further validate novel genetic testing for pulmonary fibrosis technology that can help with the early detection of the condition and improve treatment solutions. The test is being developed by the Clinical Genetics and Genomics Laboratory at Royal Brompton and Harefield hospitals. Additionally, Boehringer Ingelheim Ltd, a leading player in the market, is working on developing BI 1015550. It is a clinical development technology that can be used for treating IPF and progressive pulmonary fibrosis (PPF) among people over the age of 18 years. BI 1015550 is an oral inhibitor of the enzyme phosphodiesterase 4B (PDE4B). It has a combined effect of anti-inflammation and anti-fibrosis. Apart from drug-related developments, market players are also focusing on using advanced technologies such as artificial intelligence (AI) and machine learning (ML) for superior diagnosis. For instance, in October 2022, scientists from Brigham and Women's Hospital, NewYork-Presbyterian, Weill Cornell Medicine, the University of Chicago, and  Mayo Clinic launched a new ML-powered screening tool integrated into Electronic medical records (EMRs) for identifying patients with high-risk of IPF even before the symptoms appear.

Idiopathic Pulmonary Fibrosis Market: Challenges

High cost of treatment and disease management is a critical challenge for the market players

The global idiopathic pulmonary fibrosis industry will be challenged by the high cost of treatment and disease management. In certain cases, patients are recommended to undergo lung transplants. It is an extensive procedure causing significant expenses and long-term care. A lung transplant can cost as much as USD 930,000. Moreover, postoperative care is considerably expensive as it requires intensive care monitoring, chronic rejection monitoring, lifestyle changes, and routine health maintenance.

Idiopathic Pulmonary Fibrosis Market: Segmentation

The global idiopathic pulmonary fibrosis market is segmented based on treatment centers, drug type, and region.

Based on the treatment centers, the global market segments are hospitals, ambulatory centers, specialty facilities, and others. In 2023, the highest growth was observed in the hospitals segment driven by the increasing development of robust healthcare infrastructure and growing construction of comprehensive care-providing facilities. Additionally, the surge in understanding about IPF among medical professionals and patients has helped the market generate considerable revenue. For instance, the European Union has more than 15000 hospitals across the region.

Based on the drug type, the idiopathic pulmonary fibrosis industry divisions are pirfenidone and nintedanib.  In 2023, the highest growth was observed in the pirfenidone segment. It is expected to deliver exceptional results during the projection period. The growing incorporation of pirfenidone medicines such as Pirespa and Esbriet for treating cases of IPF will drive the segmental demand rate. However, the drug also has specific side effects. As per market research, around 21% of patients being treated by pirfenidone have discontinued the treatment due to associated adverse effects.

Idiopathic Pulmonary Fibrosis Market: Report Scope

Idiopathic Pulmonary Fibrosis Market: Regional Analysis

North America to continue dominating the market growth rate during the projection period

The global idiopathic pulmonary fibrosis market will be led by North America during the projection period. Countries such as the US and Canada have excellent medical care infrastructure. The US, for instance, is world renowned for its rare disease diagnostic and treatment facilities. The growing rate of medical tourism in the US helps the region maintain its dominance in the regional industry. In August 2023, the National Institutes of Health (NIH) published a report highlighting an experimental anticancer drug that showed effective results in treating idiopathic pulmonary fibrosis. The drug is called saracatinib. Scientists leveraged the benefits of computational predictions to identify the potential of saracatinib. In May 2023, Cumberland Pharmaceuticals Inc. announced that it had received clearance from the US FDA for an Investigational New Drug Application (IND) for a Phase II study in IPF patients. The company is expected to launch the FIGHTING FIBROSIS trial across 20 centers in the US and enroll around 128 patients. In October 2023, Bristol Myers Squibb received an FDA Breakthrough Therapy Designation for BMS-986278. It can be used for treating progressive pulmonary fibrosis (PPF).

Idiopathic Pulmonary Fibrosis Market: Competitive Analysis

The global idiopathic pulmonary fibrosis market is led by players like:

• Promedior
• Vicore Pharma
• Genentech
• Pliant Therapeutics
• Galapagos NV
• Boehringer Ingelheim
• AstraZeneca
• Bristol-Myers Squibb
• Veracyte
• Biogen
• Bellerophon Therapeutics
• FibroGen
• Gilead Sciences
• Roche
• Kadmon Holdings.

The global idiopathic pulmonary fibrosis market is segmented as follows:

By Treatment Centers

• Hospitals
• Ambulatory Centers
• Specialty Facilities

By Drug Type

• Pirfenidone
• Nintedanib

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa